Hong Kong, China

Lai-King Sy

This inventor holds 1 USPTO granted patent. Top assignee: Goldporp Pharma Limited. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lai-King Sy. Retrieved from https://idiyas.com/inventor/lai-king-sy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Lai-King Sy

Introduction

Lai-King Sy is a notable inventor based in Hong Kong, CN. He has made significant contributions to the field of pharmaceuticals, particularly in the development of osteogenic agents. His work focuses on addressing bone loss, a critical health issue affecting many individuals, especially those with osteoporosis.

Latest Patents

Lai-King Sy holds 1 patent for his invention titled "Osteogenic agents and uses thereof." This patent describes compositions and methods aimed at reducing or inhibiting bone loss in subjects in need. The pharmaceutical compositions include one or more osteogenic compounds, or their functional derivatives, in effective amounts to promote bone formation. These compositions are particularly beneficial for treating bone loss associated with osteoporosis.

Career Highlights

Lai-King Sy is associated with Goldporp Pharma Limited, where he applies his expertise in developing innovative pharmaceutical solutions. His work has the potential to significantly impact the treatment of osteoporosis and improve the quality of life for many patients.

Collaborations

Lai-King Sy has collaborated with notable colleagues, including Chi-Ming Che and Chun-Nam Lok. Their combined efforts contribute to advancing research and development in the pharmaceutical industry.

Conclusion

Lai-King Sy's innovative work in osteogenic agents showcases his commitment to addressing critical health challenges. His contributions to the field of pharmaceuticals are invaluable and highlight the importance of continued research in improving patient outcomes.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…